Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

recognized in earnings.

Net loss for the third quarter of 2007 was $3.8 million, compared to a net loss of $3.9 million in the corresponding period in 2006. Basic and diluted net loss per share was $0.15 in the three months ended September 30, 2007, on 25.1 million weighted average shares outstanding, compared to basic and diluted net loss per share of $0.29 in the three months ended September 30, 2006, on 13.4 million weighted average shares outstanding.

Nine Months Ended September 30, 2007

Total revenues were $9.1 million for the nine months ended September 30, 2007, compared to total revenues of $8.3 million for the nine months ended September 30, 2006. Substantially all of the revenues for both periods were derived from the Company's collaboration agreement with sanofi-aventis. The increase in revenues in the 2007 period was primarily due to an increase in development costs related to UVIDEM clinical trials, which are reimbursed by sanofi-aventis.

Research and development expenses were $17.0 million in each of the nine months ended June 30, 2007 and 2006. The spending related to clinical development of UVIDEM and clinical development, regulatory filings and manufacturing of L-MTP-PE increased $3.7 million in the 2007 period and was offset by a $2.5 million reduction in spending associated with development activities related to products currently on hold, as well as a $1.2 million reduction associated with lower headcount and termination of a lease agreement for certain of the Company's Paris facilities.

Selling, general and administrative expenses were $9.7 million and $7.2 million for the nine months ended September 30, 2007 and 2006, respectively. The higher expenses in 2007 include $0.5 million in fees paid to an investment advisor in connection with the private placement completed in February 2007, $1.1 million associated with accrued severance benefits and $0.5 million in bonus accruals.

Net Interest income was $3.6 milli
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... Small print and poor printing on prescription labels ... may lead to errors in taking medication, according ... and CNIB (Canadian National Institute for the Blind)., ... Pharmacists Journal , found that labels on prescription ... professionally recommended guidelines for legibility. , By simply ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... only soybean oil to provide the highest level of ... clean taste., IOWA CITY, Iowa, Feb. 12 An ... only meets the increasing,consumer demand for low trans fat foods, ... so important to food processors., Asoyia Mid Oleic Ultra ...
... N.J., Feb. 12 TeamStaff, Inc.,(Nasdaq: ... and administrative,staffing services, announced today that it ... division, RS Staffing Services, Inc., to TeamStaff,Government ... Georgia based subsidiary currently provides medical, office,administration ...
... Should be considered along with LDL cholesterol ... 12 (HealthDay News) -- A new study showing ... of cardiac trouble strengthens the case for including ... , "Triglycerides traditionally have been viewed as second-class ...
... the recent announcement by,the United States Food and Drug ... Cosmetic (botulinum toxin type A), customers are,looking for alternatives ... FDA approval in 2002 for the temporary treatment of,moderate ... 18 to 65 years,of age. In its recent communication, ...
... DALLAS, Feb. 12 The Beryl Companies announced ... president of product management,and marketing. In this newly ... at a time when new services are being ... strategies., "Mark is a welcome addition to ...
... Association Join Forces to,Educate, African-Americans on Managing ... Feb. 12 A recent survey,commissioned by the ... among African-Americans, two out of three (61,percent) expressed ... of,five (40 percent) expressed concern about developing Alzheimer,s. ...
Cached Medicine News:Health News:Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Triglycerides Linked to Coronary Disease Risk 2Health News:Triglycerides Linked to Coronary Disease Risk 3Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 4
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Calif., April 28, 2011 ... unaudited)ItemQ1 2011Q1 2010 ComparisonTotal BioMarin Revenue , $109.5 , ... increaseNaglazyme Net Product Revenue , $60.6 , 24.7% increaseAldurazyme ... Product Revenue , $26.7 , 25.9% increaseFirdapse Net Product ...
... PDI, Inc. (Nasdaq: PDII ) today announced that ... Tuesday, May 3, 2011 after the market close and host ... Eastern time to discuss the results.Access information:Date: , Wednesday, May ... 644-4654 (U.S. and Canada) or (706) 643-1203 Conference ID number: ...
Cached Medicine Technology:BioMarin Announces First Quarter 2011 Financial Results 2BioMarin Announces First Quarter 2011 Financial Results 3BioMarin Announces First Quarter 2011 Financial Results 4BioMarin Announces First Quarter 2011 Financial Results 5BioMarin Announces First Quarter 2011 Financial Results 6BioMarin Announces First Quarter 2011 Financial Results 7BioMarin Announces First Quarter 2011 Financial Results 8BioMarin Announces First Quarter 2011 Financial Results 9BioMarin Announces First Quarter 2011 Financial Results 10BioMarin Announces First Quarter 2011 Financial Results 11
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Jaguar Lumbar I/F Cage system is a ... separate the mechanical and biologic functions of ... Lumbar I/F Cage provides a device designed ... and uses autologous cancellous bone, the best ...
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
Medicine Products: